The STAMPEDE trial evaluated docetaxel added to long-term androgen deprivation therapy (ADT) for newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC). The landmark finding was:
- A Docetaxel improved median overall survival by approximately 22 months in high-volume mHSPC ✓
- B Docetaxel showed no benefit over ADT alone in mHSPC
- C Docetaxel benefit was limited to patients with visceral metastases
- D Docetaxel was inferior to abiraterone in mHSPC
Correct answer: A. Docetaxel improved median overall survival by approximately 22 months in high-volume mHSPC
Explanation
The STAMPEDE trial (and CHAARTED trial) demonstrated that upfront docetaxel added to ADT in high-volume (≥4 bone metastases or visceral disease) mHSPC improved median overall survival by approximately 17–22 months compared to ADT alone. This shifted practice toward early chemohormonal therapy. STAMPEDE also showed abiraterone acetate with ADT improved failure-free survival significantly, but the question specifically asks about docetaxel.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.